Iranian Journal of Pediatrics 2003. 13(1):42-46.

Phosphocysteamine in the Treatment of Cystinosis
A Madani, Niloofar Hadjizadeh

Abstract


Cystinosis is a relatively rare recessive autosomal inherited metabolic disease. In this metabolic anomaly free cystin is accumulated in the cell lysozymes of the different body tissues. The nephritic form of the disease begins in infancy and leads to Fanconi syndrome with polyuria, polydisia, metabolic acidosis, phosphaturia and Vitamin D-resistent rickets. If not treated, it can end in chronic kidney insufficiency. In the beginning of the disease phosphocysteamine can prevent the accumulation of cystin in the lysozymes and can hinder the progress of the disease. In our study we treated 15 cystinosis patients (7 girls, 8 boys) with phosphocystamine. The mean age at beginning of the symptoms was 8.4 months. Unfortunately, the disease was diagnosed and treatment started at a mean age of 3.58 years. Therefore, all patients had their kidney complications at the time the treatment with phosphocysteamind began. Anyhow, creatinine clearance increased after treatment in 12 patients. There was a significant relation between the time of beginning of the treatment and patients condition after treatment, i.e. the earlier the treatment began, the better was the function of the kidneys after treatment with phosphocysteamin.


Keywords


Fanconi syndrome, Phospjcysteamine, Nephropathy, Kidney clearance

Full Text: PDF
This article has been downloaded 261 times up to now.

Refbacks

  • There are currently no refbacks.


http://ijp.tums.ac.ir/public/site/images/ziaee/document5_1300

Indexing & Abstracting: ISI (Citation Index Expanded); PUBMED and PUBMED Central; SCOPUS; Embase; CINAHL; Bioline International Website; Global Health; DOAJ; IMMER; National Library for Health; SID; Iranmedex; Magiran; EMRMedex; Genamics-JournalSeek; Index Copernicus; MedBioWorld; Nutrition and Food Sciences; Open J-Gate; Ulrich Database; SJSU; EZB

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.